Axa
RIGL icon

Axa’s Rigel Pharmaceuticals RIGL Stock Holding History

Axa’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,690
Closed -$149K – 1345
2019
Q2 		$149K Sell
5,690
-3,460
-38% -$78.1K ﹤0.01% 1243
2019
Q1 		$235K Hold
9,150
– – ﹤0.01% 1242
2018
Q4 		$210K Sell
9,150
-2,810
-23% -$79.3K ﹤0.01% 1226
2018
Q3 		$384K Hold
11,960
– – ﹤0.01% 1191
2018
Q2 		$338K Buy
+11,960
New +$426K ﹤0.01% 1205
2018
Q1 		– Sell
-3,340
Closed -$130K – 1415
2017
Q4 		$130K Sell
3,340
-1,150
-26% -$43.8K ﹤0.01% 1321
2017
Q3 		$114K Buy
4,490
+10
+0.2% +$243 ﹤0.01% 1292
2017
Q2 		$122K Buy
+4,480
New +$123K ﹤0.01% 1222
2016
Q1 		– Sell
-193,481
Closed -$5.86M – 1396
2015
Q4 		$5.86M Sell
193,481
-4,067
-2% -$123K 0.03% 521
2015
Q3 		$4.88M Buy
197,548
+65,077
+49% +$1.94M 0.02% 578
2015
Q2 		$4.25M Buy
+132,471
New +$5.06M 0.02% 628

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa's RIGL Position: Q3 2019 in Review

Axa sold out of Rigel Pharmaceuticals (RIGL) in Q3 2019, closing a stake of 5,690 shares — an estimated $149K sold.

Axa first reported a position in RIGL in Q2 2015 and held it in 11 quarters. The position peaked at $5.86M in Q4 2015. 131 funds tracked by Wall St. Rank hold RIGL as of Q3 2019.

  • Axa reported no remaining Rigel Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Axa sold 5,690 Rigel Pharmaceuticals shares in Q3 2019, an estimated $149K.
  • Axa first reported a position in Rigel Pharmaceuticals in Q2 2015 and held it in 11 quarters.
  • Axa's Rigel Pharmaceuticals position peaked at $5.86M in Q4 2015.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2019.

Based on Axa's 13F filing for Q3 2019, filed 14 Nov 2019.